All In Biotech

Drug Trial Radar · NCT06573008

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications

Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 328 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

328

Planned (sponsor's estimate)

Start

Nov 11, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.

Conditions

  • Influenza, Human

Interventions

  • GP681 40mgDrug

    2 x 20mg tablets taken orally

  • GP681 SimulantDrug

    Placebo tablets matching GP681 40mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to alleviation of influenza symptomsTime frame: up to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The people's Hospital of Chizhou

    Chizhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.